1. Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms. (August 2018) Authors: Berdeja, J.; Palandri, F.; Baer, M.R.; Quick, D.; Kiladjian, J.J.; Martinelli, G.; Verma, A.; Hamid, O.; Walgren, R.; Pitou, C.; Li, P.L.; Gerds, A.T. Journal: Leukemia research Issue: Volume 71(2018) Page Start: 82 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: PHASE 1 STUDY EVALUATING LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS. (May 2023) Authors: Garcia-Manero, G.; Bachiashvili, K.; Amin, H.; Traer, E.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Cripe, L.; Berdeja, J.; Griffiths, E.; Mohan, S.; Vachhani, P.; Sano, Y.; Oganesian, A.; Keer, H.; Yacoub, A. Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Topic: AS08-Treatment/AS08f-Clinical trials – Phase II-III: RANDOMIZED PHASE 2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS. (May 2023) Authors: Garcia-Manero, G.; Bachiashvili, K.; Griffiths, E.; Traer, E.; Saini, L.; Amin, H.; Zeidan, A.; Mohan, S.; Lübbert, M.; Maness, L.; Foran, J.; Selleslag, D.; Xicoy, B.; Pollyea, D.; Sallman, D.; Al-Kali, A.; Berdeja, J.; Al-Ali, H.; Zhu, N.; Lopez, P. Font Journal: Leukemia research Issue: Volume 128(2023)Supplement Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗